The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.

The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.

Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.

Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.

Evidation, co-founded by Stanford University and GE Ventures, has picked up series E funding at a $1bn valuation.

ActionIQ has pushed its series C round to $100m following an extension from existing shareholders.

D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

RA Capital Management and Rock Springs Capital have co-led a series B round for the gene editing technology developer spun out of Stanford six months ago.

Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.